CY1107945T1 - Διφαινυλκαρβοξαμιδια υποκατεστημενα με ν-αρυλ πιπεριδινη ως αναστολεις της εκκρισης της απολιποπρωτεϊνης β - Google Patents

Διφαινυλκαρβοξαμιδια υποκατεστημενα με ν-αρυλ πιπεριδινη ως αναστολεις της εκκρισης της απολιποπρωτεϊνης β

Info

Publication number
CY1107945T1
CY1107945T1 CY20081100504T CY081100504T CY1107945T1 CY 1107945 T1 CY1107945 T1 CY 1107945T1 CY 20081100504 T CY20081100504 T CY 20081100504T CY 081100504 T CY081100504 T CY 081100504T CY 1107945 T1 CY1107945 T1 CY 1107945T1
Authority
CY
Cyprus
Prior art keywords
apolipoprotein
inhibitors
compounds
substituted
bisynylcarboxamides
Prior art date
Application number
CY20081100504T
Other languages
English (en)
Inventor
Lieven Meerpoel
Leo Jacobus Josef Backx
Peter Walter Maria Roevens
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of CY1107945T1 publication Critical patent/CY1107945T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ενώσεις διφαινυλκαρβοξαμιδίων υποκατεστημένων με Ν-αρυλ πιπεριδίνη του τύπου (I), μέθοδοι για την παρασκευή αυτών των ενώσεων, φαρμακευτικές συνθέσεις που περιλαμβάνουν τις εν λόγω ενώσεις καθώς και η χρήση των εν λόγω ενώσεων ως ένα φάρμακο για την αντιμετώπιση της υπερλιπιδαιμίας, της παχυσαρκίας και του διαβήτη τύπου II. Οι ενώσεις δρουν ως αναστολείς της απολιποπρωτεΐνης Β.
CY20081100504T 2002-08-12 2008-05-13 Διφαινυλκαρβοξαμιδια υποκατεστημενα με ν-αρυλ πιπεριδινη ως αναστολεις της εκκρισης της απολιποπρωτεϊνης β CY1107945T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078309 2002-08-12
EP03792260A EP1536796B1 (en) 2002-08-12 2003-08-05 N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion

Publications (1)

Publication Number Publication Date
CY1107945T1 true CY1107945T1 (el) 2013-09-04

Family

ID=31896911

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100504T CY1107945T1 (el) 2002-08-12 2008-05-13 Διφαινυλκαρβοξαμιδια υποκατεστημενα με ν-αρυλ πιπεριδινη ως αναστολεις της εκκρισης της απολιποπρωτεϊνης β

Country Status (32)

Country Link
US (2) US20060040989A1 (el)
EP (1) EP1536796B1 (el)
JP (1) JP4559856B2 (el)
KR (1) KR101052204B1 (el)
CN (3) CN101165053A (el)
AR (1) AR040968A1 (el)
AT (1) ATE385796T1 (el)
AU (1) AU2003250215B2 (el)
BR (1) BR0313377A (el)
CA (1) CA2494208C (el)
CY (1) CY1107945T1 (el)
DE (1) DE60319097T2 (el)
DK (1) DK1536796T3 (el)
EA (1) EA008061B1 (el)
EG (1) EG25699A (el)
ES (1) ES2301873T3 (el)
HK (1) HK1083451A1 (el)
HR (1) HRP20050103B1 (el)
IL (1) IL166795A (el)
IS (1) IS2726B (el)
MX (1) MXPA05001712A (el)
MY (1) MY136632A (el)
NO (1) NO329308B1 (el)
NZ (1) NZ538680A (el)
PA (1) PA8579901A1 (el)
PL (1) PL212405B1 (el)
PT (1) PT1536796E (el)
SI (1) SI1536796T1 (el)
TW (1) TWI342775B (el)
UA (1) UA79300C2 (el)
WO (1) WO2004017969A1 (el)
ZA (1) ZA200501225B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83510C2 (en) * 2003-12-09 2008-07-25 Янссен Фармацевтика Н.В. N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
FR2883000B1 (fr) 2005-03-14 2007-06-01 Merck Sante Soc Par Actions Si Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EP1948629A1 (en) 2005-10-31 2008-07-30 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
US8163708B2 (en) * 2006-04-03 2012-04-24 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotide
CA3024953A1 (en) 2006-04-03 2007-10-11 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US20080249130A1 (en) * 2007-02-09 2008-10-09 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
US8580756B2 (en) * 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
CA2681406A1 (en) * 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
CA2697970A1 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S Rna antagonist compounds for the modulation of fabp4/ap2
ATE505454T1 (de) * 2007-09-20 2011-04-15 Amgen Inc 1-(4-(4-benzylbenzamid)-benzyl)-azetidin-3- carboxylsäurederivate und entsprechende verbindungen als s1p-rezeptor-modulatoren zur behandlung von immunerkrankungen
EA019939B1 (ru) 2007-10-04 2014-07-30 Сантарис Фарма А/С МОДИФИЦИРОВАННЫЙ ОЛИГОМЕР ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА микроРНК В КЛЕТКЕ
EP2268811A1 (en) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2315832B1 (en) 2008-08-01 2015-04-08 Roche Innovation Center Copenhagen A/S Micro-rna mediated modulation of colony stimulating factors
WO2010122538A1 (en) * 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
SI3013959T1 (sl) 2013-06-27 2020-04-30 Roche Innovation Center Copenhagen A/S Protismiselni oligomeri in konjugati, ki ciljajo PCSK9
US9790237B2 (en) 2014-06-16 2017-10-17 Johnson Matthey Public Limited Company Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4847271A (en) * 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US5041432A (en) * 1987-01-30 1991-08-20 E. I. Du Pont De Nemours And Company Steroid derivatives useful as hypocholesterolemics
US5064856A (en) * 1989-07-31 1991-11-12 Merck & Co., Inc. Novel hmg-coa synthase inhibitors
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
EP0618803A4 (en) * 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
DE69332792T2 (de) 1992-04-20 2004-01-15 Takeda Chemical Industries Ltd 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
AU678503B2 (en) 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
WO1996010559A1 (en) 1994-10-04 1996-04-11 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
US5510379A (en) * 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
PL336481A1 (en) * 1997-04-18 2000-06-19 Pfizer Method of obtaining (1,2,3,4- tetrahydroisoquinolin -6-yl) amide of 4'-trifluoromethylbiphenyl-2-carboxylic acid and intermediate compounds
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
JO2390B1 (en) * 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Diphenylcarboxamides act as lipid-lowering agents
ES2217245T3 (es) * 2001-06-27 2004-11-01 Rs Tech Corp. Nuevo catalizador saleno quiral y metodos de obtencion de compuestos quirales a partir de epoxidos racemicos utilizando el nuevo catalizador.
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
EP1536796B1 (en) 2008-02-13
MY136632A (en) 2008-11-28
ZA200501225B (en) 2006-07-26
AR040968A1 (es) 2005-04-27
HK1083451A1 (en) 2006-07-07
KR101052204B1 (ko) 2011-07-29
DE60319097T2 (de) 2009-06-04
MXPA05001712A (es) 2005-04-19
AU2003250215B2 (en) 2009-01-22
JP2006500371A (ja) 2006-01-05
IS7622A (is) 2004-12-29
IL166795A0 (en) 2006-01-15
TWI342775B (en) 2011-06-01
NO20050563L (no) 2005-01-31
US20090156623A1 (en) 2009-06-18
EA200500348A1 (ru) 2005-08-25
KR20050026483A (ko) 2005-03-15
PT1536796E (pt) 2008-05-13
TW200412954A (en) 2004-08-01
HRP20050103A2 (en) 2006-09-30
EG25699A (en) 2012-05-22
CA2494208C (en) 2011-05-10
CA2494208A1 (en) 2004-03-04
AU2003250215A1 (en) 2004-03-11
WO2004017969A1 (en) 2004-03-04
EP1536796A1 (en) 2005-06-08
DK1536796T3 (da) 2008-06-09
NZ538680A (en) 2006-01-27
CN1674900A (zh) 2005-09-28
CN101165052A (zh) 2008-04-23
SI1536796T1 (sl) 2008-08-31
ATE385796T1 (de) 2008-03-15
CN101165053A (zh) 2008-04-23
US8258304B2 (en) 2012-09-04
HRP20050103B1 (hr) 2013-09-30
PL212405B1 (pl) 2012-09-28
ES2301873T3 (es) 2008-07-01
US20060040989A1 (en) 2006-02-23
CN101165052B (zh) 2012-04-18
UA79300C2 (en) 2007-06-11
IS2726B (is) 2011-03-15
CN100366252C (zh) 2008-02-06
PA8579901A1 (es) 2005-03-03
DE60319097D1 (de) 2008-03-27
JP4559856B2 (ja) 2010-10-13
PL373379A1 (en) 2005-08-22
IL166795A (en) 2010-11-30
NO329308B1 (no) 2010-09-27
EA008061B1 (ru) 2007-02-27
BR0313377A (pt) 2005-07-12

Similar Documents

Publication Publication Date Title
CY1107945T1 (el) Διφαινυλκαρβοξαμιδια υποκατεστημενα με ν-αρυλ πιπεριδινη ως αναστολεις της εκκρισης της απολιποπρωτεϊνης β
HK1100559A1 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
CY1109240T1 (el) Συνδυασμος που περιλαμβανει βαλσαρτανη, αμλοδιπινη και υδροχλωροθειαζιδιο
CY1121853T1 (el) Συνδυαστικη θεραπεια για την αγωγη του διαβητη
CY1106457T1 (el) Φαρμακευτικη συνθεση για τη χρηση σε θepαπεια ορμονικης υποκαταστασεως
CY1114218T1 (el) Μεθοδοι για την αγωγη διαταραχων ή παθησεων που συσχετιζονται με υπερλιπιδαιμια και υπερχοληστερολαιμια ενω ελαχιστοποιουνται οι παρενεργειες
CY1110500T1 (el) Νεα φαρμακα για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας
DE60315336D1 (de) Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
HRP20120004T1 (en) Dipeptidyl peptidase inhibitors for treating diabetes
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
CY1122429T1 (el) Αμορφη υδροχλωρικη λερκανιδιπινη
BRPI0313733A8 (pt) Uso da proteína n beta cinase
CY1110929T1 (el) Παραγωγα πυριδαζινονης ως αγωνιστες υποδοχεων θυρεοειδικης ορμονης
NO20022857L (no) Nye P2X7-reseptoragonister for bruk i behandling av inflammatoriske, immun- eller kardiovaskul¶re sykdommer
NO20033732L (no) N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.
CY1112451T1 (el) Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης
CY1112173T1 (el) Η χρηση της cilobradine ή των φαρμακευτικα αποδεκτων αλατων αυτης για την θεραπεια ή την προληψη της καρδιακης ανεπαρκειας
JO2390B1 (en) Diphenylcarboxamides act as lipid-lowering agents
CY1108413T1 (el) Ενεσιμη φαρμακευτικη συνθεση που περιλαμβανει αιθανολη για την αγωγη των δισκοπαθειων
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
CY1105308T1 (el) Θepαπεια για υπep-ουρικαιμια
JO2529B1 (en) Ariel pybradine is a substitute for phenyl carboxymides
CY1109966T1 (el) Υποκατεστημενα αραλκυλοπαραγωγα